{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:45:22Z","timestamp":1792633522415,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13760-024-02519-8","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T02:01:52Z","timestamp":1714096912000},"page":"1251-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0705-9393","authenticated-orcid":false,"given":"Anand Kumar","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-0701","authenticated-orcid":false,"given":"Mainak","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-7096","authenticated-orcid":false,"given":"Saraj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashim Kumar","family":"Boro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-0582","authenticated-orcid":false,"given":"Manish","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simmi","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyayani","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"suppl_5","key":"2519_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro Oncol 19(suppl_5):v1-88. https:\/\/doi.org\/10.1093\/neuonc\/nox158","journal-title":"Neuro Oncol"},{"issue":"1","key":"2519_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00381-022-05694-2","volume":"39","author":"AK Das","year":"2023","unstructured":"Das AK, Mani SK, Singh SK, Kumar S (2023) Management and outcome of unusual pediatric brain tumors: challenges experienced at a tertiary care center of a developing country. Childs Nerv Syst 39(1):169\u2013183. https:\/\/doi.org\/10.1007\/s00381-022-05694-2","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"2519_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-019-03287-9","volume":"145","author":"FE El-Khouly","year":"2019","unstructured":"El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, Hendrikse NH, Kaspers GJL, Loizos G et al (2019) Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol 145(1):177\u201384. https:\/\/doi.org\/10.1007\/s11060-019-03287-9","journal-title":"J Neurooncol"},{"issue":"4","key":"2519_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520-537.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017","journal-title":"Cancer Cell"},{"key":"2519_CR5","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.1200\/jco.2015.33.15_suppl.10004","volume":"33","author":"MW Kieran","year":"2015","unstructured":"Kieran MW, Hargrave DR, Cohen KJ, Aerts I, Dunkel IJ, Hummel TR et al (2015) Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high-and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST). JCO 33:10004\u201310004","journal-title":"JCO"},{"key":"2519_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867154","volume":"13","author":"L Antonucci","year":"2022","unstructured":"Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F (2022) CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol 13:867154. https:\/\/doi.org\/10.3389\/fimmu.2022.867154","journal-title":"Front Immunol"},{"issue":"7","key":"2519_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","volume":"24","author":"E de Billy","year":"2022","unstructured":"de Billy E, Pellegrino M, Orlando D, Pericoli G, Ferretti R, Businaro P et al (2022) Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol 24(7):1150\u20131163. https:\/\/doi.org\/10.1093\/neuonc\/noab300","journal-title":"Neuro Oncol"},{"key":"2519_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.742561","author":"KB Leszczynska","year":"2021","unstructured":"Leszczynska KB, Jayaprakash C, Kaminska B, Mieczkowski J (2021) Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2021.742561","journal-title":"Front Genet"},{"issue":"2","key":"2519_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-019-00502-2","volume":"14","author":"P Merli","year":"2019","unstructured":"Merli P, Algeri M, Del Bufalo F, Locatelli F (2019) Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematol Malig Rep 14(2):94\u2013105. https:\/\/doi.org\/10.1007\/s11899-019-00502-2","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"2519_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY (2020) Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38(4):473\u2013488. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005","journal-title":"Cancer Cell"},{"issue":"6","key":"2519_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","volume":"23","author":"D Haydar","year":"2021","unstructured":"Haydar D, Houke H, Chiang J, Yi Z, Od\u00e9 Z, Caldwell K et al (2021) Cell-surface antigen profiling of pediatric brain tumors: B7\u2013H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol 23(6):999\u20131011. https:\/\/doi.org\/10.1093\/neuonc\/noaa278","journal-title":"Neuro Oncol"},{"key":"2519_CR12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha B, Inal C, Owonikoko TK (2020) Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol 10:1000. https:\/\/doi.org\/10.3389\/fonc.2020.01000","journal-title":"Front Oncol"},{"issue":"9","key":"2519_CR13","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B et al (2017) CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther 25(9):2214\u20132224. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.012","journal-title":"Mol Ther"},{"issue":"5","key":"2519_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3\u2013K27M+ diffuse midline gliomas. Nat Med 24(5):572\u2013579. https:\/\/doi.org\/10.1038\/s41591-018-0006-x","journal-title":"Nat Med"},{"issue":"7903","key":"2519_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"11","key":"2519_CR16","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.3390\/ijms22115775","volume":"22","author":"J Ma","year":"2021","unstructured":"Ma J, Chen CC, Li M (2021) Macrophages\/microglia in the glioblastoma tumor microenvironment. Int J Mol Sci 22(11):5775. https:\/\/doi.org\/10.3390\/ijms22115775","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2519_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1568009616666160813191240","volume":"17","author":"C Dello Russo","year":"2017","unstructured":"Dello Russo C, Lisi L, Tentori L, Navarra P, Graziani G, Combs CK (2017) Exploiting microglial functions for the treatment of glioblastoma. Curr Cancer Drug Targets 17(3):267\u2013281. https:\/\/doi.org\/10.2174\/1568009616666160813191240","journal-title":"Curr Cancer Drug Targets"},{"key":"2519_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0553-x","author":"GL Lin","year":"2018","unstructured":"Lin GL, Nagaraja S, Filbin MG, Suv\u00e0 ML, Vogel H, Monje M (2018) Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-018-0553-x","journal-title":"Acta Neuropathol Commun"},{"key":"2519_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fphar.2020.00368","volume":"11","author":"H Gr\u00e9goire","year":"2020","unstructured":"Gr\u00e9goire H, Roncali L, Rousseau A, Ch\u00e9rel M, Delneste Y, Jeannin P et al (2020) Targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma. Front Pharmacol 11:368. https:\/\/doi.org\/10.3389\/fphar.2020.00368","journal-title":"Front Pharmacol"},{"issue":"8","key":"2519_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043339","volume":"7","author":"JR Engler","year":"2012","unstructured":"Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N et al (2012) Increased microglia\/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS ONE 7(8):e43339. https:\/\/doi.org\/10.1371\/journal.pone.0043339","journal-title":"PLoS ONE"},{"issue":"5","key":"2519_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL et al (2020) Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 26(5):720\u2013731. https:\/\/doi.org\/10.1038\/s41591-020-0827-2","journal-title":"Nat Med"},{"issue":"6","key":"2519_CR22","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s13346-021-01079-1","volume":"11","author":"OM Turk","year":"2021","unstructured":"Turk OM, Woodall RC, Gutova M, Brown CE, Rockne RC, Munson JM (2021) Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. Drug Deliv Transl Res 11(6):2448\u20132467. https:\/\/doi.org\/10.1007\/s13346-021-01079-1","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"2519_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"2519_CR24","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321\u20133330","journal-title":"Blood"},{"key":"2519_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT (2014) Grupp SA managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20:119\u2013122","journal-title":"Cancer J"},{"key":"2519_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0299-5","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C et al (2016) Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-016-0299-5","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2519_CR27","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264\u20131270. https:\/\/doi.org\/10.1038\/nm.1882","journal-title":"Nat Med"},{"issue":"23","key":"2519_CR28","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23):6050\u20136056. https:\/\/doi.org\/10.1182\/blood-2011-05-354449","journal-title":"Blood"},{"issue":"9","key":"2519_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2217\/imt-2016-0021","volume":"8","author":"Z Perez Horta","year":"2016","unstructured":"Perez Horta Z, Goldberg JL, Sondel PM (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8(9):1097\u20131117. https:\/\/doi.org\/10.2217\/imt-2016-0021","journal-title":"Immunotherapy"},{"issue":"1","key":"2519_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2519_CR31","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF et al (2018) Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 26(7):1855\u20131866. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003","journal-title":"Mol Ther"},{"key":"2519_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL et al (2018) Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics 11:20\u201338. https:\/\/doi.org\/10.1016\/j.omto.2018.08.002","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"2519_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"issue":"8","key":"2519_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15(8):1145\u20131154. https:\/\/doi.org\/10.1517\/14712598.2015.1046430","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2519_CR35","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K et al (2018) Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 23(7):2130\u20132141. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.051","journal-title":"Cell Rep"},{"issue":"13","key":"2519_CR36","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J et al (2017) Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep 20(13):3025\u20133033. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.002","journal-title":"Cell Rep"},{"issue":"48","key":"2519_CR37","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S et al (2016) Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA 113(48):E7788\u2013E7797. https:\/\/doi.org\/10.1073\/pnas.1610544113","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2519_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cancers12020375","volume":"12","author":"K Zimmermann","year":"2020","unstructured":"Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS et al (2020) Design and characterization of an \u201call-in-one\u201d Lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines. Cancers (Basel) 12(2):375. https:\/\/doi.org\/10.3390\/cancers12020375","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2519_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu M-F, Liu H, Dotti G et al (2017) Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res 5(7):571\u2013581. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0376","journal-title":"Cancer Immunol Res"},{"key":"2519_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cimid.2018.12.006","volume":"63","author":"A Nicolas-Boluda","year":"2019","unstructured":"Nicolas-Boluda A, Donnadieu E (2019) Obstacles to T cell migration in the tumor microenvironment. Comp Immunol Microbiol Infect Dis 63:22\u201330. https:\/\/doi.org\/10.1016\/j.cimid.2018.12.006","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"1","key":"2519_CR41","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M et al (2019) CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10(1):4016. https:\/\/doi.org\/10.1038\/s41467-019-11869-4","journal-title":"Nat Commun"},{"issue":"5","key":"2519_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S et al (2020) Locoregionally administered B7\u2013H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med 26(5):712\u2013719. https:\/\/doi.org\/10.1038\/s41591-020-0821-8","journal-title":"Nat Med"},{"issue":"26","key":"2519_CR43","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375(26):2561\u20132569. https:\/\/doi.org\/10.1056\/NEJMoa1610497","journal-title":"N Engl J Med"},{"issue":"3","key":"2519_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ (2013) Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36(3):437\u2013449. https:\/\/doi.org\/10.1007\/s10545-013-9608-0","journal-title":"J Inherit Metab Dis"},{"key":"2519_CR45","doi-asserted-by":"publisher","first-page":"203636132211502","DOI":"10.1177\/20363613221150218","volume":"15","author":"AK Das","year":"2023","unstructured":"Das AK, Singh SK, Bhavana K, Kumar S (2023) Posterior fossa giant adenoid cystic carcinoma with skull base invasion mimicking glomus jugulare: a case report and review of literature. Rare Tumors 15:203636132211502. https:\/\/doi.org\/10.1177\/20363613221150218","journal-title":"Rare Tumors"},{"issue":"1","key":"2519_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK (2020) The blood-brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2519_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.12773","volume":"290","author":"D Akhavan","year":"2019","unstructured":"Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE (2019) CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev 290(1):60\u201384. https:\/\/doi.org\/10.1111\/imr.12773","journal-title":"Immunol Rev"},{"issue":"6","key":"2519_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"issue":"3","key":"2519_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152196","volume":"11","author":"S Thomas","year":"2016","unstructured":"Thomas S, Straathof K, Himoudi N, Anderson J, Pule M (2016) An optimized GD2-targeting Retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS ONE 11(3):e0152196. https:\/\/doi.org\/10.1371\/journal.pone.0152196","journal-title":"PLoS ONE"},{"issue":"10","key":"2519_CR50","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S et al (2016) Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res 4(10):869\u2013880. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0230","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"2519_CR51","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"issue":"16","key":"2519_CR52","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/nejmoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/nejmoa1407222","journal-title":"N Engl J Med"},{"issue":"6","key":"2519_CR53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540\u2013549. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025","journal-title":"J Clin Oncol"},{"issue":"355","key":"2519_CR54","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E et al (2016) Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621","journal-title":"Sci Transl Med"},{"issue":"1","key":"2519_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM et al (2017) Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 25(1):285\u2013295. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.020","journal-title":"Mol Ther"},{"key":"2519_CR56","doi-asserted-by":"publisher","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, et al (2016) Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): Results from the pivotal phase 2 Zuma-1. Blood 128(22):LBA-6-LBA-6. https:\/\/doi.org\/10.1182\/blood.v128.22.lba-6.lba-6","DOI":"10.1182\/blood.v128.22.lba-6.lba-6"},{"issue":"6","key":"2519_CR57","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"issue":"9967","key":"2519_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3","journal-title":"Lancet"},{"issue":"16","key":"2519_CR59","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/nejmoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al (2013) Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518. https:\/\/doi.org\/10.1056\/nejmoa1215134","journal-title":"N Engl J Med"},{"key":"2519_CR60","unstructured":"Nih.gov. [cited 2023 Apr 4]. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06"},{"issue":"9","key":"2519_CR61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, H\u00e9bert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa067373","journal-title":"N Engl J Med"},{"key":"2519_CR62","unstructured":"GD2 CAR T cells in diffuse intrinsic pontine gliomas (DIPG) & spinal diffuse midline glioma (DMG). Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04196413"},{"key":"2519_CR63","unstructured":"Kernel Networks Inc. C7R-GD2.CAR T cells for patients with GD2-expressing brain tumors (GAIL-B). Case Medical Research. 2019 [cited 2023 Apr 4]; https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04099797"},{"key":"2519_CR64","unstructured":"T cells expressing HER2-specific chimeric antigen receptors (CAR) for patients with HER2-positive CNS tumors\u2014full text view\u2014Clinicaltrials.gov. Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02442297"},{"key":"2519_CR65","unstructured":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent\/Refractory Pediatric CNS Tumors. Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03500991"},{"key":"2519_CR66","unstructured":"Case Medical Research. Study of B7-H3-specific CAR T cell locoregional immunotherapy for diffuse intrinsic pontine glioma\/diffuse Midline glioma and recurrent or refractory pediatric central nervous system tumors. Case Medical Research. 2019 [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04185038"},{"key":"2519_CR67","unstructured":"B7-H3-specific chimeric antigen receptor autologous T-Cell therapy for pediatric patients with solid tumors (3CAR). Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04897321"},{"key":"2519_CR68","unstructured":"Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma. Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02208362"},{"key":"2519_CR69","unstructured":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors. Clinicaltrials.gov. [cited 2023 Apr 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03638167"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02519-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T22:45:29Z","timestamp":1721774729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02519-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2519"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02519-8","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}